Neoplasms

Symptoms and General Pathology

All Conditions

Nervous System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Substance Related Disorders

Rare Diseases

Neoplasm Metastasis

Recurrence

Glioblastoma

Glioma

Endodermal Sinus Tumor

Teratoma

Brain Neoplasms

Central Nervous System Neoplasms

Medulloblastoma

Germinoma

Nervous System Neoplasms

Astrocytoma

Ependymoma

Oligodendroglioma

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Choriocarcinoma

Drug-Related Side Effects and Adverse Reactions

Brain Diseases

Central Nervous System Diseases

Chemically-Induced Disorders

Germ Cells Tumors

Central Nervous System Germinoma

Brain Tumor, Childhood

Neuroepithelioma

Childhood Brain Stem Glioma

Supratentorial Primitive Neuroectodermal Tumor

Medulloblastoma, Childhood

Cerebellar Astrocytoma, Childhood

Cerebral Astrocytoma, Childhood

Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Pharmaceutical Solutions

Natriuretic Agents

Anti-Infective Agents

Respiratory System Agents

Micronutrients

Vitamins

Etoposide

Cyclophosphamide

Carboplatin

Lenograstim

Mannitol

Etoposide phosphate

Acetylcysteine

N-monoacetylcystine

Sodium thiosulfate

Vitamin A

Retinol palmitate

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Enzyme Inhibitors

Antiviral Agents

Expectorants

Antioxidants

Protective Agents

Antidotes

Diuretics

Antitubercular Agents

Anti-Bacterial Agents

Chelating Agents

Retinol

filgrastim

acetylcysteine

(200 mg/m2/day; total dose 400 mg/m2) will be infused i.a. over 10 minutes, in 50-180 cc of normal saline.

carboplatin

(330 mg/m2/day; total dose 660 mg/m2) will be infused i.v. in 25-50 cc of normal saline, over approximately 10 minutes.

cyclophosphamide

(200 mg/m2/day; total dose 400 mg/m2) will be infused i.v. in 25-100 cc of normal saline, over approximately 10 minutes, immediately following the cyclophosphamide.

etoposide phosphate

(25%) delivered i.a. at a pre-determined flow rate over 30 seconds. The flow rate will be determined by iodinated contrast injection and fluoroscopy as the lowest infusion rate in which there is retrograde flow from the arterial catheter. The rate and volume of mannitol infused will be approximately 4-12 cc/sec x 30 seconds.

mannitol

STS is available as a 25% (250 mg/ml) solution. The dose of STS administered 4 hours after carboplatin is 16 gm/m2. The dose of STS administered 8 hours after carboplatin is 16 gm/m2. Actual dose to be administered will be determined and mixed with an equivalent amount of sterile water (1 ml:1 ml) for infusion.

sodium thiosulfate

Edward A. Neuwelt, MD

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, etoposide phosphate, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Mannitol may help chemotherapy work better by making it easier for these drugs to get to the tumor. Chemoprotective drugs, such as acetylcysteine and sodium thiosulfate, may protect normal cells from the side effects of chemotherapy. Giving acetylcysteine together with mannitol, combination chemotherapy, and sodium thiosulfate may be an effective treatment for malignant brain tumors.

PURPOSE: This phase I trial is studying the side effects and best dose of acetylcysteine when given together with mannitol, combination chemotherapy, and sodium thiosulfate in treating children with malignant brain tumors.

OBJECTIVES:

Primary

* Determine the toxicity and maximum tolerated dose of acetylcysteine when given in combination with blood-brain barrier disruption treatment with mannitol, combination chemotherapy comprising cyclophosphamide, etoposide phosphate, and carboplatin, and delayed high-dose sodium thiosulfate in pediatric patients with malignant brain tumors.

Secondary

* Determine the blood/bone marrow toxicity of this regimen in these patients.
* Determine tumor response in patients treated with this regimen.

OUTLINE: This is a dose-escalation study of acetylcysteine.

Patients receive acetylcysteine IV over 30-60 minutes followed, at least 15 minutes later, by x-ray-guided femoral artery catheterization under general anesthesia on days 1 and 2. After placement of the catheter, patients receive cyclophosphamide IV over 10 minutes, etoposide phosphate IV over 10 minutes, mannitol intra-arterially (IA) over 30 seconds, and carboplatin IA over 10 minutes also on days 1 and 2. Patients then receive high-dose sodium thiosulfate IV over 15 minutes 4 hours after completion of carboplatin. Some patients may receive a second dose of sodium thiosulfate 8 hours after completion of carboplatin. Beginning 48 hours after the last dose of chemotherapy on day 2, patients receive filgrastim (G-CSF) subcutaneously once daily for 7-10 days or until blood counts recover. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of acetylcysteine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 3 patients are treated at the MTD.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Phase I Dose Escalation Study of N-Acetylcysteine Administered in Conjunction With Carboplatin, Cyclophosphamide, and Etoposide Phosphate BBBD, in Children With Malignant Brain Tumors

National Cancer Institute (NCI)

OHSU Knight Cancer Institute

Professor

Infections

Behaviors and Mental Disorders

Heart and Blood Diseases

Immune System Diseases

Blood and Lymph Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Ear, Nose, and Throat Diseases

Syndrome

Acute Kidney Injury

Fatigue

Communicable Diseases

Renal Insufficiency

Depression

Heart Failure

Hypersensitivity

Multiple Myeloma

Neoplasms, Plasma Cell

Arrhythmias, Cardiac

Peripheral Nervous System Diseases

Pneumonia

Jaundice

Vertigo

Dizziness

Sleepiness

Thromboembolism

Confusion

Tumor Lysis Syndrome

Teratogenesis

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Acute Graft Versus Host Disease

Pomalidomide

Among relapsed or refractory multiple myeloma patients, all patients who received Pomalyst will be targeted in this surveillance.

Jinshu Cho

1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form of the surveillance will be completed at the time when the planned number of patients to be enrolled is reached. During a period until conditions for approval are removed, a system enabling to retrospectively collect appropriate information based on patient data from RevMate® will be, as necessary, maintained.
2. Planned duration of the surveillance Anticipated to be 2 years and 6 months from the start date of release of Pomalyst

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Pomalyst®Capsules Special Use-results Surveillance (All-case Surveillance)

Number of participants with adverse events

Celgene

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors	NCT00238173	Bone Marrow Sup... Brain and Centr... Drug/Agent Toxi... Long-term Effec...	filgrastim acetylcysteine carboplatin cyclophosphamid... etoposide phosp... mannitol sodium thiosulf...	1 Year - 18 Years	OHSU Knight Cancer Institute
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg	NCT02921828	Multiple Myelom...		18 Years -	Celgene

Spots Global Cancer Trial Database for bone marrow suppression